A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy
Open Access
- 4 June 2024
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (8) , 1-11
Abstract
Background: The liver function reserve has a significant impact on the therapeutic effects of anti-programmed cell death-1 (PD-1) for hepatocellular carcinoma (HCC). This study aimed to comprehensively evaluate the ability of liver-function-based indicators to predict prognosis and construct a novel prognostic score for HCC patients with anti-PD-1 immunotherapy. Methods: Between July 2018 and January 2020, patients diagnosed with HCC who received anti-PD-1 treatment were screened for inclusion in the study. The valuable prognostic liver-function-based indicators were selected using Cox proportional hazards regression analysis to build a novel liver-function-indicators-based signature (LFIS). Concordance index (C-index), the area under the receiver operating characteristic (ROC) curve (AUC), and Kaplan–Meier survival curves were utilized to access the predictive performance of LFIS. Results: A total of 434 HCC patients who received anti-PD-1 treatment were included in the study. The LFIS, based on alkaline phosphatase-to-albumin ratio index, Child–Pugh score, platelet-albumin score, aspartate aminotransferase-to-lymphocyte ratio index, and gamma-glutamyl transpeptidase-to-lymphocyte ratio index, was constructed and identified as an independent risk factor for patient survival. The C-index of LFIS for overall survival (OS) was 0.692, which was higher than the other single liver-function-based indicator. The AUC of LFIS at 6-, 12-, 18-, and 24-month were 0.74, 0.714, 0.747, and 0.865 for OS, respectively. Patients in the higher-risk LFIS group were associated with both worse OS and PFS. An online and easy-to-use calculator was further constructed for better application of the LFIS signature. Conclusion: The LFIS score had an excellent prognosis prediction ability superior to every single liver-function-based indicator for anti-PD-1 treatment in HCC patients. It is a reliable, easy-to-use tool to stratify risk for OS and PFS in HCC patients who received anti-PD-1 treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82172579, 82172579, 82172579, 82172579, 82172579, 82172579, 82172579, 82172579)
This publication has 52 references indexed in Scilit:
- Comprehensive and Integrative Genomic Characterization of Hepatocellular CarcinomaCell, 2017
- ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD EraJournal of Gastroenterology and Hepatology, 2017
- Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resectionInternational Journal of Surgery, 2016
- γ‐Glutamyltransferase and cancer risk: The Korean cancer prevention studyInternational Journal of Cancer, 2015
- Inhibition of Alkaline Phosphatase: An Emerging New Drug TargetMini-Reviews in Medicinal Chemistry, 2015
- Gamma-Glutamyl Transpeptidase2014
- Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort studyHepatology International, 2013
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- X-TileClinical Cancer Research, 2004
- Nuclear localization of alkaline phosphatase in cultured human cancer cellsMedical Molecular Morphology, 2003